- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Depression Research and Treatment
Volume 2013 (2013), Article ID 256841, 8 pages
Reduced Treatment-Emergent Sexual Dysfunction as a Potential Target in the Development of New Antidepressants
1Clinical and Experimental Sciences Academic Unit, Faculty of Medicine, University of Southampton, Southampton SO14 3DT, UK
2Department of Psychiatry, University of Cape Town, Cape Town, South Africa
3Department of Pathophysiology and Transplantation, University of Milan and Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy
4First Department of Psychiatry, Eginition Hospital, Athens University Medical School, 11528 Athens, Greece
Received 1 October 2012; Revised 18 December 2012; Accepted 3 January 2013
Academic Editor: Charles B. Nemeroff
Copyright © 2013 David S. Baldwin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- L. R. DeRogatis and A. L. Burnett, “The epidemiology of sexual dysfunctions,” Journal of Sexual Medicine, vol. 5, no. 2, pp. 289–300, 2008.
- R. W. Lewis, K. S. Fugl-Meyer, G. Corona et al., “Definitions/epidemiology/risk factors for sexual dysfunction,” Journal of Sexual Medicine, vol. 7, no. 4, pp. 1598–1607, 2010.
- A. Nicolosi, E. O. Laumann, D. B. Glasser, E. D. Moreira, A. Paik, and C. Gingell, “Sexual behavior and sexual dysfunctions after age 40: the global study of sexual attitudes and behaviors,” Urology, vol. 64, no. 5, pp. 991–997, 2004.
- R. O. Rosen, W. A. Fisher, I. Eardley, C. Niederberger, A. Nadel, and M. Sand, “The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population,” Current Medical Research and Opinion, vol. 20, no. 5, pp. 607–617, 2004.
- L. Dennerstein, P. Koochaki, I. Barton, and A. Graziottin, “Hypoactive sexual desire disorder in menopausal women: a survey of Western European women,” Journal of Sexual Medicine, vol. 3, no. 2, pp. 212–222, 2006.
- R. Basson, P. Rees, R. Wang, A. L. Montejo, and L. Incrocci, “Sexual function in chronic illness,” Journal of Sexual Medicine, vol. 7, no. 1, pp. 374–388, 2010.
- J. Angst, “Sexual problems in healthy and depressed persons,” International Clinical Psychopharmacology, vol. 13, supplement 6, pp. S1–S3, 1998.
- J. M. Cyranowski, J. Bromberger, A. Youk, K. Matthews, H. M. Kravitz, and L. H. Powell, “Lifetime depression history and sexual function in women at midlife,” Archives of Sexual Behavior, vol. 33, no. 6, pp. 539–548, 2004.
- J. M. Hegeman, R. M. Kok, R. C. van der Mast, and E. J. Giltay, “Phenomenology of depression in older compared with younger adults: meta-analysis,” British Journal of Psychiatry, vol. 200, pp. 275–281, 2012.
- C. F. Lin, Y. Y. Juang, J. K. Wen, C. Y. Liu, and C. I. Hung, “Correlations between sexual dysfunction, depression, anxiety, and somatic symptoms among patients with major depressive disorder,” Chang Gung Medical Journal, vol. 35, no. 4, pp. 323–331, 2012.
- S. M. Laurent and A. D. Simons, “Sexual dysfunction in depression and anxiety: conceptualizing sexual dysfunction as part of an internalizing dimension,” Clinical Psychology Review, vol. 29, no. 7, pp. 573–585, 2009.
- N. C. C. Vulink, D. Denys, L. Bus, and H. G. M. Westenberg, “Sexual pleasure in women with obsessive-compulsive disorder?” Journal of Affective Disorders, vol. 91, no. 1, pp. 19–25, 2006.
- G. Aksaray, B. Yelken, C. Kaptanoǧlu, S. Oflu, and M. Özaltin, “Sexuality in women with obsessive compulsive disorder,” Journal of Sex and Marital Therapy, vol. 27, no. 3, pp. 273–277, 2001.
- K. Williams and M. F. Reynolds, “Sexual dysfunction in major depression,” CNS Spectrums, vol. 11, supplement 9, pp. 19–23, 2006.
- V. S. L. Williams, D. S. Baldwin, S. L. Hogue, S. E. Fehnel, K. A. Hollis, and H. M. Edin, “Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey,” Journal of Clinical Psychiatry, vol. 67, no. 2, pp. 204–210, 2006.
- V. S. L. Williams, H. M. Edin, S. L. Hogue, S. E. Fehnel, and D. S. Baldwin, “Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey,” Journal of Psychopharmacology, vol. 24, no. 4, pp. 489–496, 2010.
- A. Serretti and A. Chiesa, “Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis,” Journal of Clinical Psychopharmacology, vol. 29, no. 3, pp. 259–266, 2009.
- H. Gartlehner, R. A. Hansen, L. C. Morgan, et al., “Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder. An updated meta-analysis,” Annals of Internal Medicine, vol. 155, no. 11, pp. 772–785, 2011.
- K. Demyttenaere and L. Jaspers, “Review: bupropion and SSRI-induced side effects,” Journal of Psychopharmacology, vol. 22, no. 7, pp. 792–804, 2008.
- N. Watanabe, I. M. Omori, A. Nakagawa et al., “Mirtazapine versus other anti-depressive agents for depression,” Cochrane Database of Systematic Reviews, vol. 12, no. 2, Article ID CD006528, 2007.
- A. Benelli, C. Frigeri, A. Bertolini, and S. Genedani, “Influence of mirtazapine on the sexual behavior of male rats,” Psychopharmacology, vol. 171, no. 3, pp. 250–258, 2004.
- A. L. Montejo, N. Prieto, A. Terleira et al., “Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale,” Journal of Psychopharmacology, vol. 24, no. 1, pp. 111–120, 2010.
- S. H. Kennedy, S. Rizvi, K. Fulton, and J. Rasmussen, “A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR,” Journal of Clinical Psychopharmacology, vol. 28, no. 3, pp. 329–333, 2008.
- I. B. Hickie and N. L. Rogers, “Novel melatonin-based therapies: potential advances in the treatment of major depression,” The Lancet, vol. 378, no. 9791, pp. 621–631, 2011.
- A. Zourkova and E. Hadasova, “Paroxetine-induced conversion of cytochrome P450 2D6 phenotype and occurence of adverse effects,” General Physiology and Biophysics, vol. 22, no. 1, pp. 103–113, 2003.
- A. Zourkova, E. Ceskova, E. Hadašová, and B. Ravčuková, “Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity,” Journal of Sex and Marital Therapy, vol. 33, no. 4, pp. 343–355, 2007.
- A. Zourkova, O. Slanar, J. Jarkovsky, I. Palcikova, E. Pindurova, and M. Cvanova, “MDR1 in paroxetine-induced sexual dysfunction,” Journal of Sex & Marital Therapy, vol. 39, no. 1, pp. 71–78, 2013.
- I. Nazareth, P. Boynton, and M. King, “Problems with sexual function in people attending London general practitioners: cross sectional study,” British Medical Journal, vol. 327, no. 7412, pp. 423–426, 2003.
- S. Read, M. King, and J. Watson, “Sexual dysfunction in primary medical care: prevalence, characteristics and detection by the general practitioner,” Journal of Public Health Medicine, vol. 19, no. 4, pp. 387–391, 1997.
- W. Rief, Y. Nestoriuc, A. Von Lilienfeld-Toal et al., “Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis,” Drug Safety, vol. 32, no. 11, pp. 1041–1056, 2009.
- E. M. Haberfellner, “A review of the assessment of antidepressant-induced sexual dysfunction used in randomized, controlled clinical trials,” Pharmacopsychiatry, vol. 40, no. 5, pp. 173–182, 2007.
- S. J. Rizvi, N. W. Yeung, and S. H. Kennedy, “Instruments to measure sexual dysfunction in community and psychiatric populations,” Journal of Psychosomatic Research, vol. 70, no. 1, pp. 99–109, 2011.
- F. Giuliano and W. J. G. Hellstrom, “The pharmacological treatment of premature ejaculation,” BJU International, vol. 102, no. 6, pp. 668–675, 2008.
- H. A. Fink, R. MacDonald, I. R. Rutks, and T. J. Wilt, “Trazodone for erectile dysfunction: a systematic review and meta-analysis,” BJU International, vol. 92, no. 4, pp. 441–446, 2003.
- D. Baldwin, K. Bridgman, and C. Buis, “Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine,” Journal of Psychopharmacology, vol. 20, no. 1, pp. 91–96, 2006.
- D. Baldwin, R. A. Moreno, and M. Briley, “Resolution of sexual dysfunction during acute treatment of major depression with milnacipran,” Human Psychopharmacology, vol. 23, no. 6, pp. 527–532, 2008.
- U. Werneke, S. Northey, and D. Bhugra, “Antidepressants and sexual dysfunction,” Acta Psychiatrica Scandinavica, vol. 114, no. 6, pp. 384–397, 2006.
- X. H. Hu, S. A. Bull, E. M. Hunkeler et al., “Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate,” Journal of Clinical Psychiatry, vol. 65, no. 7, pp. 959–965, 2004.
- H. Dueñas, A. Lee, A. J. M. Brnabic et al., “Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study,” International Journal of Psychiatry in Clinical Practice, vol. 15, no. 2, pp. 80–90, 2011.
- M. J. Taylor, L. Rudkin, and K. Hawton, “Strategies for managing antidepressant-induced sexual dysfunction: systematic review of randomised controlled trials,” Journal of Affective Disorders, vol. 88, no. 3, pp. 241–254, 2005.
- R. Balon and R. T. Segraves, “Survey of treatment practices for sexual dysfunction(s) associated with anti-depressants,” Journal of Sex and Marital Therapy, vol. 34, no. 4, pp. 353–365, 2008.
- A. J. Rothschild, “Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday,” American Journal of Psychiatry, vol. 152, no. 10, pp. 1514–1516, 1995.
- D. S. Baldwin, “Sexual dysfunction associated with antidepressant drugs,” Expert Opinion on Drug Safety, vol. 3, no. 5, pp. 457–470, 2004.
- R. Amiaz, H. G. Pope, T. Mahne et al., “Testosterone gel replacement improves sexual function in depressed men taking serotonergic antidepressants: a randomized, placebo-controlled clinical trial,” Journal of Sex and Marital Therapy, vol. 37, no. 4, pp. 243–254, 2011.
- H. G. Nurnberg, P. L. Hensley, A. J. Gelenberg, M. Fava, J. Lauriello, and S. Paine, “Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial,” Journal of the American Medical Association, vol. 289, no. 1, pp. 56–64, 2003.
- H. G. Nurnberg, P. L. Hensley, J. R. Heiman, H. A. Croft, C. Debattista, and S. Paine, “Sildenafil treatment of women with antidepressant-associated sexual dysfunction: a randomized controlled trial,” Journal of the American Medical Association, vol. 300, no. 4, pp. 395–404, 2008.
- R. T. Segraves, J. Lee, R. Stevenson, D. J. Walker, W. C. Wang, and R. A. Dickson, “Tadalafil for treatment of erectile dysfunction in men on antidepressants,” Journal of Clinical Psychopharmacology, vol. 27, no. 1, pp. 62–66, 2007.
- D. Michelson, K. Kociban, R. Tamura, and M. F. Morrison, “Mirtazapine, yohimbine or olanzapine augmentation therapy for serotonin reuptake-associated female sexual dysfunction: a randomized, placebo controlled trial,” Journal of Psychiatric Research, vol. 36, no. 3, pp. 147–152, 2002.
- M. Fava, C. M. Dording, R. A. Baker et al., “Effects of adjunctive aripiprazole on sexual functioning in patients with major depressive disorder and an inadequate response to standard antidepressant monotherapy: a post hoc analysis of 3 randomized, double-blind, placebo-controlled studies,” Primary Care Companion to the Journal of Clinical Psychiatry, vol. 13, no. 1, pp. e1–e10, 2011.
- K.-E. Andersson, “Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction,” Pharmacological Reviews, vol. 63, no. 4, pp. 811–859, 2011.
- B. Musicki, T. Liu, G. A. Lagoda, T. J. Bivalacqua, T. D. Strong, and A. L. Burnett, “Endothelial nitric oxide synthase regulation in female genital tract structures,” Journal of Sexual Medicine, vol. 6, supplement 3, pp. 247–253, 2009.
- H. G. Nurnberg, S. N. Seidman, A. J. Gelenberg, M. Fava, R. Rosen, and R. Shabsigh, “Depression, antidepressant therapies, and erectile dysfunction: clinical trials of sildenafil citrate (Viagra) in treated and untreated patients with depression,” Urology B, vol. 60, supplement 2, pp. 58–66, 2002.
- R. C. Rosen, S. N. Seidman, M. A. Menza et al., “Quality of life, mood, and sexual function: a path analytic model of treatment effects in men with erectile dysfunction and depressive symptoms,” International Journal of Impotence Research, vol. 16, no. 4, pp. 334–340, 2004.
- G. Wegener, B. H. Harvey, B. Bonefeld et al., “Increased stress-evoked nitric oxide signalling in the Flinders sensitive line (FSL) rat: a genetic animal model of depression,” International Journal of Neuropsychopharmacology, vol. 13, no. 4, pp. 461–473, 2010.
- N. Liebenberg, B. H. Harvey, L. Brand, G. Wegener, and C. B. Brink, “Chronic treatment with the phosphodiesterase type 5 inhibitors sildenafil and tadalafil display anxiolytic effects in Flinders Sensitive Line rats,” Metabolic Brain Disease, vol. 27, no. 3, pp. 337–340, 2012.
- C. B. Brink, J. D. Clapton, B. E. Eagar, and B. H. Harvey, “Appearance of antidepressant-like effect by sildenafil in rats after central muscarinic receptor blockade: evidence from behavioural and neuro-receptor studies,” Journal of Neural Transmission, vol. 115, no. 1, pp. 117–125, 2008.
- S. L. Clark, D. E. Adkins, K. Aberg et al., “Pharmacogenomic study of side-effects for antidepressant treatment options in STAR∗D,” Psychological Medicine, vol. 42, no. 6, pp. 1151–1162, 2012.
- K. Kurose, K. Hiratsuka, K. Ishiwata, et al., “Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression,” Psychiatry Research, vol. 198, no. 3, pp. 424–429, 2012.
- J. R. Bishop, J. Moline, V. L. Ellingrod, S. K. Schultz, and A. H. Clayton, “Serotonin 2A -1438 G/A and G-protein beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects,” Neuropsychopharmacology, vol. 31, no. 10, pp. 2281–2288, 2006.
- C. S. Liang, P. S. Ho, and K. T. Chiang, “Su HC. 5-HT(2A) receptor -1438 G/A polymorphism and serotonergic antidepressant-induced sexual dysfunction in male patients with major depressive disorder: a prospective exploratory study,” Journal of Sexual Medicine. In press.
- C. M. Dording, D. Mischoulon, I. Shyu, J. E. Alpert, and G. I. Papakostas, “SAMe and sexual functioning,” European Psychiatry, vol. 27l, no. 6, pp. 451–454, 2012.
- C. M. Dording, L. Fisher, G. Papakostas et al., “A double-blind, randomized, pilot dose-finding study of maca root (L. Meyenii) for the management of SSRI-induced sexual dysfunction,” CNS Neuroscience and Therapeutics, vol. 14, no. 3, pp. 182–191, 2008.
- A. Modabbernia, H. Sohrabi, A. A. Nasehi et al., “Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial,” Psychopharmacology, vol. 223, no. 4, pp. 381–388, 2012.
- M. J. Norden, “Buspirone treatment of sexual dysfunction associated with selective serotonin re-uptake inhibitors,” Depression, vol. 2, no. 2, pp. 109–112, 1994.
- M. Landen, E. Erikkson, H. Agren, and T. Fahlen, “Effects of buspirone on sexual function in depressed patients treated with selective serotonin reuptake inhibitors,” Journal of Clinical Psychopharmacology, vol. 19, no. 3, pp. 268–271, 1999.
- L. F. Fabre, A. H. Clayton, L. C. Smith, I. Goldstein, and L. R. Derogatis, “The effect of gepirone-ER in the treatment of sexual dysfunction in depressed men,” Journal of Sexual Medicine, vol. 9, no. 3, pp. 821–829, 2012.
- L. Citrome, “Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?” International Journal of Clinical Practice, vol. 66, no. 4, pp. 356–368, 2012.
- A. H. Clayton, S. H. Kennedy, J. B. Edwards, S. Gallipoli, and C. R. Reed, “The effect of vilazodone on sexual function during the treatment of major depressive disorder,” Journal of Sexual Medicine. In press.
- D. S. Baldwin, H. Loft, and M. Dragheim, “A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of LuAA21004 in acute treatment of major depressive disorder (MDD),” European Neuropsychopharmacology, vol. 22, no. 7, pp. 482–491, 2012.
- D. Baldwin, J. Hutchison, K. Donaldson, B. Shaw, and A. Smithers, “Selective serotonin re-uptake inhibitor treatment-emergent sexual dysfunction: randomized double-blind placebo-controlled parallel-group fixed-dose study of a potential adjuvant compound, VML-670,” Journal of Psychopharmacology, vol. 22, no. 1, pp. 55–63, 2008.
- S. J. Sukoff Rizzo, C. Pulicicchio, J. E. Malberg et al., “5-HT1A receptor antagonism reverses and prevents fluoxetine-induced sexual dysfunction in rats,” International Journal of Neuropsychopharmacology, vol. 12, no. 8, pp. 1045–1053, 2009.
- A. Cipriani, T. A. Furukawa, G. Salanti et al., “Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis,” The Lancet, vol. 373, no. 9665, pp. 746–758, 2009.
- A. H. Clayton, J. Zajecka, J. M. Ferguson, J. K. Filipiak-Reisner, M. T. Brown, and G. E. Schwartz, “Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder,” International Clinical Psychopharmacology, vol. 18, no. 3, pp. 151–156, 2003.
- S. Langworth, O. Bodlund, and H. Ågren, “Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder,” Journal of Clinical Psychopharmacology, vol. 26, no. 2, pp. 121–127, 2006.
- P. Tran, P. Skolnick, P. Czobor et al., “Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial,” Journal of Psychiatric Research, vol. 46, no. 1, pp. 64–71, 2012.